Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Covalon Technologies Ltd. (COV.V)
Mississauga, ON, CA
Covalon Technologies Ltd., a Canadian company based in Mississauga, innovates, develops, manufactures, and commercializes medical technologies and products globally. Its operations span major international markets, including North America, Europe, the Middle East, Asia, and Latin America, with licensing agreements in place. The company leverages three distinct proprietary technology platforms. Firstly, its collagen matrix platform underpins a family of products aimed at treating a variety of chronic and infected wounds, such as diabetic, pressure, and venous ulcers, as well as donor and graft sites, traumatic injuries healing by secondary intention, dehisced surgical wounds, and first- and second-degree burns. Secondly, an antimicrobial silicone adhesive platform is incorporated into pre- and post-surgical and vascular access products; these are specifically engineered to provide broad-spectrum antimicrobial protection by eliminating bacteria or yeast on contact. Thirdly, a unique medical coating platform employs a proprietary photo-polymerization process to generate active grafting sites, enabling the initiation and growth of new polymer chains directly on existing medical devices. Covalon's product portfolio, branded under "Covalon," encompasses advanced wound care dressings, surgical and peri-operative solutions, and infection management tools. These offerings reach a diverse clientele, including hospitals, specialized wound and burn centers, acute and long-term care facilities, home health care agencies, and physicians' offices, via a combination of direct sales and extensive third-party distribution networks.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.16% | +8.74% | +14.87% | +17.89% | +19.15% | +28.74% | -15.47% | +4.67% | +50.34% | +88.24% | -53.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+5.3% ★ Q1'26: +15.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-32.9% Q1'26: +155.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+3.5% Q1'26: -15.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+6.3% ★ Q1'26: +10.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+13.2% ★ Q1'26: +27.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15.0% Q1'26: -0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.75× ★ Q1'26: 0.38× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
Sep 2028 1 Rev. Ana. 1 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
Sep 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.56M
est: 50.00M (-60.9%)
|
18.15M
est: 68.90M (-73.7%)
|
26.60M
est: 73.70M (-63.9%)
|
31.17M
est: 32.12M (-3.0%)
|
32.82M
est: 36.00M (-8.8%)
|
35.18M
35.18M – 35.18M
-2.3% YoY
|
39.90M
39.90M – 39.90M
+13.4% YoY
|
42.88M
42.88M – 42.88M
+7.5% YoY
|
45.79M
45.79M – 45.79M
+6.8% YoY
|
48.94M
48.94M – 48.94M
+6.9% YoY
|
| EBITDA |
1.54M
est: -6.58M (+123.4%)
|
-8.11M
est: -9.07M (+10.6%)
|
-3.56M
est: -9.70M (+63.3%)
|
3.14M
est: -1.99M (+257.8%)
|
3.01M
est: -2.23M (+235.2%)
|
-2.18M
-2.18M – -2.18M
+2.3% YoY
|
-2.47M
-2.47M – -2.47M
-13.4% YoY
|
-2.65M
-2.65M – -2.65M
-7.5% YoY
|
-2.84M
-2.84M – -2.84M
-6.8% YoY
|
-3.03M
-3.03M – -3.03M
-6.9% YoY
|
| EBIT |
838.3K
est: -8.49M (+109.9%)
|
-9.14M
est: -11.69M (+21.8%)
|
-4.53M
est: -12.51M (+63.8%)
|
2.15M
est: -3.21M (+167.0%)
|
2.06M
est: -3.60M (+157.2%)
|
-3.51M
-3.51M – -3.51M
+2.3% YoY
|
-3.99M
-3.99M – -3.99M
-13.4% YoY
|
-4.28M
-4.28M – -4.28M
-7.5% YoY
|
-4.57M
-4.57M – -4.57M
-6.8% YoY
|
-4.89M
-4.89M – -4.89M
-6.9% YoY
|
| Net Income |
23.48M
est: 558.0K (+4,107.5%)
|
-9.66M
est: 8.37M (-215.5%)
|
-4.46M
est: 10.60M (-142.1%)
|
2.67M
est: 3.63M (-26.4%)
|
2.06M
est: 279.0K (+637.7%)
|
2.51M
2.51M – 2.51M
+800.0% YoY
|
3.35M
3.35M – 3.35M
+33.3% YoY
|
4.18M
4.18M – 4.18M
+25.0% YoY
|
5.02M
5.02M – 5.02M
+20.0% YoY
|
5.86M
5.86M – 5.86M
+16.7% YoY
|
| SGA |
6.72M
est: 27.32M (-75.4%)
|
13.48M
est: 37.65M (-64.2%)
|
15.57M
est: 40.28M (-61.3%)
|
13.21M
est: 15.89M (-16.9%)
|
12.42M
est: 17.81M (-30.3%)
|
17.41M
17.41M – 17.41M
-2.3% YoY
|
19.75M
19.75M – 19.75M
+13.4% YoY
|
21.22M
21.22M – 21.22M
+7.5% YoY
|
22.66M
22.66M – 22.66M
+6.8% YoY
|
24.22M
24.22M – 24.22M
+6.9% YoY
|
| EPS |
0.08
est: 0.02 (+313.0%)
|
-0.38
est: 0.30 (-226.7%)
|
-0.18
est: 0.38 (-147.4%)
|
0.11
est: 0.13 (-15.4%)
|
0.08
est: 0.01 (+651.0%)
|
0.09
0.09 – 0.09
+800.0% YoY
|
0.12
0.12 – 0.12
+33.3% YoY
|
0.15
0.15 – 0.15
+25.0% YoY
|
0.18
0.18 – 0.18
+20.0% YoY
|
0.21
0.21 – 0.21
+16.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brent Ashton | Chief Executive Officer & Director | 735.6K | male |
| Gerry Arambula | President of Covalon Technologies AG Ltd. | 634.8K | — |
| Hamed Abbasian | Vice President of Business Development | 413.0K | male |
| Kimberley Crooks | COO & Director | 366.7K | female |
| Katie Martinovich | Chief Financial Officer | 253.6K | female |
| Valerio DiTizio | Co-Founder, Chief Scientific Officer & Vice President | 216.0K | — |
| Greg Leszczynski | Vice President of Human Resources | — | male |
| Saleha Assadzada | Executive Assistant to the Chief Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for COV.V
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
